Contezolid is under clinical development by MicuRx Pharmaceuticals and currently in Phase III for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. According to GlobalData, Phase III drugs for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Contezolid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Contezolid is a next-generation oxazolidinone antibiotic. It is formulated as tablets for oral route of administration. Contezolid is indicated for the treatment of complicated skin and soft tissue infection.
Contezolid (MRX-I) is under development for the treatment of community-acquired methicillin-resistant Staphylococcus aureus (MRSA), acute bacterial skin and skin structure infections, vancomycin-resistant enterococci (VRE) infections including complicated skin and soft tissue infections and moderate or severe diabetic foot infections. The drug candidate is administered orally in the form of tablet. MRX-I is a next-generation oxazolidinone antibiotic that acts by targeting 23S rRNA.
MicuRx Pharmaceuticals overview
MicuRx Pharmaceuticals (MicuRx) is a developer of antibiotics for drug-resistant bacterial infections. The company develops a pipeline of antimicrobial agents using its proprietary drug discovery platform to treat both gram-positive and gram-negative bacterial infections. It offers product candidates which include MRX-I, an oxazolidinone antibiotic, which is intended for the treatment of methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci infections. MicuRx also develops preclinical candidates for gram-positive and gram-negative bacterial infections. It has operations in the US and China. MicuRx is headquartered in Foster City, California, the US.
For a complete picture of Contezolid’s drug-specific PTSR and LoA scores, buy the report here.